Boston Scientific (BSX) Could Be 27% Undervalued Following Earnings Growth Focus

Boston Scientific (BSX) is back in focus as investors weigh projections for year-over-year gains in upcoming earnings and revenue, along with commentary highlighting organic growth and expanding free cash flow margins.

Recent trading tells two stories on Boston Scientific. Short-term momentum is soft, with the share price down 9% over 30 days and 53% year to date. In contrast, the 5-year total shareholder return of about 2% signals muted long-run gains despite recurring product recalls and upcoming leadership change.

Compare Boston Scientific's setup with a curated group of medical device and healthcare peers that also screen as value opportunities through our 30 high quality undervalued stocks.

Boston Scientific now trades near US$44 while analyst targets and intrinsic value estimates cluster far higher. Is that discount a genuine margin of safety or a warning label on the recent slide?

Most Popular Narrative: 26.9% Undervalued

On the most widely followed view, Boston Scientific screens as undervalued, with a fair value of about $61 against a last close near $44.62. That gap hinges on whether planned restructuring and new platforms can translate into sustained earnings power.

Enhanced scale and operational efficiency are now anchored by a comprehensive restructuring program targeting about US$500m of annual run rate savings exiting 2029, combined with a US$2b share repurchase completed in Q2 2026. Together these actions are directed at supporting operating margin resilience and EPS growth even as near term guidance reflects WATCHMAN, EP and cyberattack related pressure.

See why 81 investors see Boston Scientific as 27% undervalued.

Result: Fair Value of $61.07 (UNDERVALUED)

Still, the Boston Scientific story can break if WATCHMAN and Electrophysiology weakness drags on or if the large Penumbra deal proves harder to integrate than expected.

Find out about the key risks to this Boston Scientific narrative.

Next Steps

Mixed messages in the Boston Scientific story so far. Consider acting while sentiment is this divided and evaluate both the bullish and cautious angles for yourself with 4 key rewards and 1 important warning sign.

Looking for more Boston Scientific style investment ideas?

Do not stop your research with Boston Scientific. Fresh ideas often come from scanning beyond the obvious, and you may miss out if you overlook that edge.

• Target higher quality value opportunities by sorting companies that combine cash generation with solid fundamentals through the 30 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with stronger finances using the list of solid balance sheet and fundamentals (23 results).
• Hunt for underfollowed opportunities that may be flying under the radar through the 16 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com